News Website

Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology - Frontiers

Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology Frontiers

Published: Dec. 8, 2025, 10:41 a.m.

Read Full Article

A rare curious case of ureteric dissection in a patient with vaginal vault recurrence of endometrial carcinoma - SpringerOpen

A rare curious case of ureteric dissection in a patient with vaginal vault recurrence of endometrial carcinoma SpringerOpen

Published: Nov. 25, 2025, 8:52 a.m.

Read Full Article

Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.

Mesonephric-like adenocarcinoma (MLA) is a rare and aggressive gynecologic malignancy that has only been recognized in the last decade. It arises in the endometrium, ovaries, and other extrauterine sites (often …

Published: Nov. 24, 2025, midnight

Read Full Article

MLA endometrial cancer endometrial carcinoma extrauterine carcinoma gynecologic cancer gynecologic carcinoma mesonephric carcinoma mesonephric-like carcinoma ovarian cancer ovarian carcinoma

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어

Published: Nov. 13, 2025, 5:50 a.m.

Read Full Article

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma Targeted Oncology

Published: Nov. 12, 2025, 7:08 p.m.

Read Full Article

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - BioSpace

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma BioSpace

Published: Nov. 12, 2025, 4:01 a.m.

Read Full Article

Navigating Tumour Microenvironment in Endometrial Carcinoma: A Comprehensive Review Integrating Immunohistochemistry, Single-cell RNA-sequencing and Spatial Transcriptomics - Frontiers

Navigating Tumour Microenvironment in Endometrial Carcinoma: A Comprehensive Review Integrating Immunohistochemistry, Single-cell RNA-sequencing and Spatial Transcriptomics Frontiers

Published: Oct. 28, 2025, 4:44 p.m.

Read Full Article

Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas - Nature

Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas Nature

Published: Oct. 20, 2025, 9:19 a.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.

Read Full Article

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.

Read Full Article

Latest Articles

Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology - Frontiers

A rare curious case of ureteric dissection in a patient with vaginal vault recurrence of endometrial carcinoma - SpringerOpen

Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - BioSpace

Navigating Tumour Microenvironment in Endometrial Carcinoma: A Comprehensive Review Integrating Immunohistochemistry, Single-cell RNA-sequencing and Spatial Transcriptomics - Frontiers

Shifted assembly and function of mSWI/SNF family subcomplexes underlie targetable dependencies in dedifferentiated endometrial carcinomas - Nature

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

Subscribe to Our Newsletter